Sage Therapeutics, Inc. (SG7.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:49AM CEST. Market open.
Currency in EUR
Valuation measures4
| Market cap (intra-day) | 670.87M |
| Enterprise value | 13.35M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 7.96 |
| Price/book (mrq) | 1.03 |
| Enterprise value/revenue | 0.16 |
| Enterprise value/EBITDA | N/A |
Trading information
Stock price history
| Beta (5Y monthly) | 0.91 |
| 52-week change 3 | -76.19% |
| S&P500 52-week change 3 | 27.84% |
| 52-week high 3 | 55.00 |
| 52-week low 3 | 10.15 |
| 50-day moving average 3 | 14.34 |
| 200-day moving average 3 | 18.34 |
Share statistics
| Avg vol (3-month) 3 | 47 |
| Avg vol (10-day) 3 | 4 |
| Shares outstanding 5 | 60.18M |
| Implied shares outstanding 6 | 64.22M |
| Float 8 | 47.52M |
| % held by insiders 1 | 12.47% |
| % held by institutions 1 | 99.62% |
| Shares short 4 | N/A |
| Short ratio 4 | N/A |
| Short % of float 4 | N/A |
| Short % of shares outstanding 4 | N/A |
| Shares short (prior month ) 4 | N/A |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Currency in USD.Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -1,489.18% |
Management effectiveness
| Return on assets (ttm) | -31.98% |
| Return on equity (ttm) | -54.72% |
Income statement
| Revenue (ttm) | 91.06M |
| Revenue per share (ttm) | 1.52 |
| Quarterly revenue growth (yoy) | 139.90% |
| Gross profit (ttm) | N/A |
| EBITDA | -507.26M |
| Net income avi to common (ttm) | -503.14M |
| Diluted EPS (ttm) | -7.73 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 717.01M |
| Total cash per share (mrq) | 11.91 |
| Total debt (mrq) | 3.31M |
| Total debt/equity (mrq) | 0.47% |
| Current ratio (mrq) | 12.22 |
| Book value per share (mrq) | 11.73 |
Cash flow statement
| Operating cash flow (ttm) | -424.74M |
| Levered free cash flow (ttm) | -232.9M |
© 2024 Yahoo. All rights reserved.